Cost-benefit analysis of sustained-release bupropion, nicotine patch, or both for smoking cessation

Preventive Medicine

Volumn 30, Issue 3, 2000, Pages 209-216

  Nielsen, K ^a   Fiore, M C ^b  

^a GLAXOSMITHKLINE   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Bupropion; Cost benefit; Economic analysis; Nicotine transdermal patch; Smoking cessation

Indexed keywords

AMFEBUTAMONE; NICOTINE;

ARTICLE; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; HUMAN; PRIORITY JOURNAL; SMOKING CESSATION; SUSTAINED RELEASE FORMULATION; TRANSDERMAL PATCH;

EID: 0034015074     PISSN: 00917435     EISSN: None     Source Type: Journal    
DOI: 10.1006/pmed.1999.0627     Document Type: Article

References (21)

1. U.S. Department of Health and Human Services, Reducing the health consequences of smoking: 25 years of progress. Atlanta: Centers for Disease Control, Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 1989. [DHHS Publication No. CDC 89-8411].
2. Bartlett J, Miller L, Rice D, Max W. Medical-care expenditures attributable to cigarette smoking: United States, 1993. MMWR. 43:1994;469-472.
3. Jackson F N, Holle RH O. Smoking: perspectives in 1985. Prim Care. 12:1985;197-216.
4. Weis W L. Can you afford to hire smokers. Pers Admin. 1981;71-78.
5. McGhan W F, Smith M D. Pharmacoeconomic analysis of smoking-cessation interventions. Am J Health Syst Pharm. 53:1996;77-79.
6. Lightwood J M, Stanton A. Short-term economic and health benefits of smoking cessation: myocardial infarction and stroke. Circulation. 96:1997;1089-1096.
7. Barendregt J J, Bonneux L, van der Maas P J. The health care costs of smoking. N Engl J Med. 337:1997;1052-1057.
8. Wasley M A, McNagny S E, Phillips V L, Ahluwalia J S. The cost-effectiveness of the nicotine transdermal patch for smoking cessation. Prev Med. 26:1997;264-270.
9. Cromwell J, Bartosch W J, Fiore M C, Hasselblad V, Baker T. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. JAMA. 278:1997;1759-1766.
10. Jorenby D E, Leischow S J, Nides M A, Rennard S I, Johnston A, Hughes A R. Effect of sustained release bupropion, a nicotine patch, or their combination for smoking cessation. N Engl J Med. 340:1999;685-691.
11. DATA 3.0. TreeAge Software, 1997.
12. 1998 Drug topics redbook. 1998;Medical Economics, Montvale.
13. U.S. Bureau of the Census, Statistical abstract of the United States: 1997, 117th ed. Washington, 1997.
14. Borland R, Cappiello M, Owen N. Leaving work to smoke. Addiction. 92:1997;1361-1368.
15. Kristein M M. How much can business expect to profit from smoking cessation. Prev Med. 12:1983;358-381.
16. Bertera R L. The effects of behavioral risks on absenteeism and health care costs in the workplace. J Occup Med. 33:1991;1119-1124.
17. Warner K E, Smith R J, Smith D G, Fries B E. Health and economic implications of a work-site smoking-cessation program: A simulation analysis. J Occup Environ Med. 38:1996;981-992.
18. Fiore M C, Smith S S, Jorenby D E, Baker T B. The effectiveness of the nicotine patch for smoking cessation: A meta analysis. JAMA. 271:1994;1940-1947.
19. MMWR. 45:1996;588-590.
20. Hatziandreu E J, Pierce J P, Lefkopoulou M, Fiore M C, Mills S L, Novotny T E. Quitting smoking in the United States in 1986. J Natl Cancer Inst. 82:1990;1402-1406.
21. McPhillips-Tangum C. Results from the First Annual Survey on Addressing Tobacco in Managed Care. Tobacco Control. 7:1998;S11-3.